Healios K.K Gets FDA Nod for Global ARDS Phase 3 Trial; Shares Up 10%
Healios K.K (TYO:4593), a biotech firm specializing in regenerative medicine, has secured FDA approval for its global Phase 3 trial, "REVIVE-ARDS," to test MultiStem for acute respiratory distress syndrome (ARDS) caused by pneumonia, according to a Monday filing on the Tokyo Stock Exchange.
The trial will use ventilator-free days as the primary endpoint and include interim analyses of 300 and 400 patients, with a maximum of 550 participants.
The company will finalize study details and consult Japanese regulators for conditional approval based on previous positive Phase 2 results. Shares of the company were up 10% in recent trade.
Price (JPY): $236.00, Change: $+22, Percent Change: +10.28%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.